NCT03428009

Brief Summary

The purpose of this study is to (1) investigate the effect of known dystonia-causing mutations on brain structure and function, to (2) identify structural brain changes that differ between clinical phenotypes of dystonia, and to (3) collect DNA, detailed family history, and clinical phenotypes from patients with idiopathic dystonia with the goal of identifying new dystonia-related genes. Investigators will be recruiting both healthy control subjects and subjects with any form of dystonia. For this study there will be a maximum of two study visit involving a clinical assessment, collection of medical and family history, task training session, an MRI using the learned tasks, and finally a blood draw for genetic analysis. In total, these visits will take 3-5 hours. If the dystonia subjects receive botulinum toxin injections for treatment, the participants and their matched controls will be asked to come for a second visit.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
200

participants targeted

Target at P75+ for all trials

Timeline
16mo left

Started Mar 2018

Longer than P75 for all trials

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress86%
Mar 2018Sep 2027

First Submitted

Initial submission to the registry

February 2, 2018

Completed
7 days until next milestone

First Posted

Study publicly available on registry

February 9, 2018

Completed
20 days until next milestone

Study Start

First participant enrolled

March 1, 2018

Completed
9.5 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

September 1, 2027

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

September 1, 2027

Last Updated

June 6, 2025

Status Verified

June 1, 2025

Enrollment Period

9.5 years

First QC Date

February 2, 2018

Last Update Submit

June 3, 2025

Conditions

Keywords

DystoniaControlMagnetic Resonance ImagineGenotypePhenotype

Outcome Measures

Primary Outcomes (2)

  • Structural or functional imaging of dystonia and control groups

    Identify structural or functional imaging measures that distinguish (a) dystonia patients from matched controls, (b) between clinically-defined forms of dystonia

    3-5 hours at each study visit

  • Genetic Analysis of dystonia and control groups

    Identify polymorphisms in genes known to cause dystonia that affect the structural or functional imaging measures in dystonia patients and to identify new genes associated with dystonia.

    30 min

Study Arms (2)

Dystonia group

Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.

Other: Magnetic Resonance Imaging

Control Group

Both groups will have blood drawn, undergo clinical assessments, the collection of medical and family history, and an Magnetic Resonance Imaging. This is an observational study and there is no intervention.

Other: Magnetic Resonance Imaging

Interventions

Study interventions are minimal risk.

Also known as: Blood Draw for Genetic testing, Clinical Assessments
Control GroupDystonia group

Eligibility Criteria

Age11 Years+
Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Investigators will recruit both healthy participants and individuals diagnosed with dystonia of any form for this study. Each Dystonia subject will be matched 1:1 with an unrelated control subject based on: 1) age, +/- 3 years (adults), +/- 1 year (16-18y), +/- 6 months (11-15y); 2) handedness, as determined by the Edinburgh Handedness Inventory, 3) gender, and 4) self-identified racial or ethnic background.

You may qualify if:

  • Dystonia group
  • Previous diagnosis of dystonia which include but is not limited to:
  • cervical dystonia (50 subjects)
  • blepharospasm (25 subjects)
  • limb dystonia (50 subjects)
  • spasmodic dysphonia (25 subjects)
  • segmental dystonia
  • multi-focal dystonia
  • Any childhood-onset dystonia (25 subjects) Age \> 11 years
  • Control group:
  • No prior dystonia diagnosis (175 subjects) Age \> 11 years

You may not qualify if:

  • Dystonia group Prior history of or concurrent neurological or psychiatric diagnosis - depression and/or anxiety accepted Current use of non-dystonia neuroactive medications - SSRI/medication for depression and/or anxiety accepted Current use of cervical brace designed for dystonia treatment Prior structural brain injury
  • Control group:
  • History of or current neurological or psychiatric diagnosis - depression and/or anxiety accepted, but must not be in active phase Current use of any neuroactive medication, SSRI/medication for depression and/or anxiety accepted

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University of Texas Southwestern Medical Center

Dallas, Texas, 75390, United States

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

Investigators will be collecting blood samples once ( two 8.5 mL Vacutainer tubes) at the participants first study visit to be sent to MGH for genetic analysis. Investigators will aliquot the whole blood collected into cyrovials and ship them overnight on dry ice to the MGH tissue culture bank to be stored and processed. No identifiable information will be sent with the blood samples.

MeSH Terms

Conditions

DystoniaDystonic DisordersDystonia 6, torsionDystonia, Dopa-responsiveParoxysmal nonkinesigenic dyskinesiaChoreoathetosis-Spasticity, EpisodicEpisodic Kinesigenic Dyskinesia 2Familial paroxysmal dystoniaMyoclonic dystoniaParoxysmal Nonkinesigenic Dyskinesia 2Dystonia 12

Interventions

Magnetic Resonance SpectroscopyBlood Specimen CollectionGenetic Testing

Condition Hierarchy (Ancestors)

DyskinesiasNeurologic ManifestationsNervous System DiseasesSigns and SymptomsPathological Conditions, Signs and SymptomsMovement DisordersCentral Nervous System Diseases

Intervention Hierarchy (Ancestors)

Spectrum AnalysisChemistry Techniques, AnalyticalInvestigative TechniquesSpecimen HandlingClinical Laboratory TechniquesDiagnostic Techniques and ProceduresDiagnosisPuncturesSurgical Procedures, OperativeGenetic TechniquesGenetic ServicesHealth ServicesHealth Care Facilities Workforce and ServicesDiagnostic ServicesPreventive Health Services

Central Study Contacts

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Associate Professor

Study Record Dates

First Submitted

February 2, 2018

First Posted

February 9, 2018

Study Start

March 1, 2018

Primary Completion (Estimated)

September 1, 2027

Study Completion (Estimated)

September 1, 2027

Last Updated

June 6, 2025

Record last verified: 2025-06

Data Sharing

IPD Sharing
Will share

Data and/or sample collection was specifically for research and subjects indicated that their data could be shared with other scientists. Investigators will only send coded data and/or samples with no identifying information. In addition, all whole blood for DNA samples collected for this protocol will be sent for DNA sequencing and genetic analysis at Massachusetts General Hospital in Dr. Nutan Sharma's lab. In addition at Massachusetts General Tissue Culture Core in the Dystonia Partners Research Biobank investigators will contribute the subject's deidentified DNA sample from this protocol for use in future genetic research regarding dystonia.

Time Frame
DNA samples will be stored indefinitely

Locations